Treatment of Community-Acquired Pneumonia: A Case Report and Current Treatment Dilemmas

Table 5

of 2007 IDSA/ATS guidelines for outpatient treatment of community-acquired pneumonia [4].

Conditions	Recommended treatment	Further detail
Region with >25% infection rate with “high-level” macrolide-resistant S. pneumoniae	Consider the nonmacrolide alternatives below
Previously healthy and no risk factors for DRSP	Macrolide (preferred) or doxycycline	Macrolides: azithromycin, clarithromycin, or erythromycin
Comorbidities, including the following: (i) Recent use of antimicrobials; (ii) Other risks for DRSP	Either; respiratory fluoroquinolone; or; β-lactam plus macrolide (or doxycycline instead of macrolide)	Fluoroquinolones: moxifloxacin, gemifloxacin, or levofloxacin; Preferred β-lactam: high-dose amoxicillin or amoxicillin-clavulanate

distillation of recommendation is not intended to replace the guidelines, which contain details not shown here; DRSP, drug-resistant S. pneumoniae.